Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in ...
TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it ...
Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023. This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD. Daneshmand ...
POTOMAC supports 1 year of durvalumab with BCG induction and maintenance therapy as a potential new treatment in BCG-naïve, high-risk NMIBC,” said Maria De Santis, MD.
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
NEW ORLEANS -- Add-On IL15RaFc superagonist N-803 (VesAnktiva) to Bacillus Calmette-Guérin (BCG) treatment led to "a clinically meaningful benefit" in BCG-unresponsive non-muscle invasive bladder ...
Hosted on MSN
Bladder cancer treatment reprograms bone marrow to boost immune system's cancer-fighting ability
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...
Anktiva is combined with BCG, or Bacillus Calmette-Guérin, an immunotherapy drug delivered to the bladder through a catheter.
Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback